Intriguingly, reduction of A1 expression sensitizes Abl-dependent tumor cells to imatinib, thereby opening a potential therapeutic avenue to improve treatment efficacy of ABL-kinase inhibitors in BCR-ABL-driven disease. This evidence concerns the gene ABL1 and neoplasm.